ID   BRCA1_RAT               Reviewed;        1817 AA.
AC   O54952; P97951;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   02-OCT-2024, entry version 180.
DE   RecName: Full=Breast cancer type 1 susceptibility protein homolog;
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:P38398};
DE   AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
GN   Name=Brca1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9892727; DOI=10.1007/s003359900935;
RA   Bennett L.M., Brownlee H.A., Hagavik S., Wiseman R.W.;
RT   "Sequence analysis of the rat brca1 homolog and its promoter region.";
RL   Mamm. Genome 10:19-25(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 8-222.
RC   STRAIN=Wistar Kyoto; TISSUE=Spleen;
RX   PubMed=8761410; DOI=10.1093/carcin/17.8.1561;
RA   Chen K.S., Shepel L.A., Haag J.D., Heil G.M., Gould M.N.;
RT   "Cloning, genetic mapping and expression studies of the rat Brca1 gene.";
RL   Carcinogenesis 17:1561-1566(1996).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 1589-1817.
RX   PubMed=11877378; DOI=10.1101/gad.959202;
RA   Joo W.S., Jeffrey P.D., Cantor S.B., Finnin M.S., Livingston D.M.,
RA   Pavletich N.P.;
RT   "Structure of the 53BP1 BRCT region bound to p53 and its comparison to the
RT   Brca1 BRCT structure.";
RL   Genes Dev. 16:583-593(2002).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that specifically mediates the
CC       formation of 'Lys-6'-linked polyubiquitin chains and plays a central
CC       role in DNA repair by facilitating cellular responses to DNA damage. It
CC       is unclear whether it also mediates the formation of other types of
CC       polyubiquitin chains. The BRCA1-BARD1 heterodimer coordinates a diverse
CC       range of cellular pathways such as DNA damage repair, ubiquitination
CC       and transcriptional regulation to maintain genomic stability. Regulates
CC       centrosomal microtubule nucleation. Required for appropriate cell cycle
CC       arrests after ionizing irradiation in both the S-phase and the G2 phase
CC       of the cell cycle. Required for FANCD2 targeting to sites of DNA
CC       damage. Inhibits lipid synthesis by binding to inactive phosphorylated
CC       ACACA and preventing its dephosphorylation. Contributes to homologous
CC       recombination repair (HRR) via its direct interaction with PALB2, fine-
CC       tunes recombinational repair partly through its modulatory role in the
CC       PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
CC       Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation
CC       and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-
CC       mediated ubiquitination of RBBP8. Acts as a transcriptional activator.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:P38398};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Heterodimer with BARD1. Part of the BRCA1-associated genome
CC       surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1,
CC       ATM, BLM, PMS2 and the MRE11-RAD50-NBN protein (MRN) complex. This
CC       association could be a dynamic process changing throughout the cell
CC       cycle and within subnuclear domains. Component of the BRCA1-A complex,
CC       at least composed of BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36,
CC       BABAM2 and BABAM1/NBA1. Interacts (via the BRCT domains) with ABRAXAS1
CC       (phosphorylated form); this is important for recruitment to sites of
CC       DNA damage. Can form a heterotetramer with two molecules of ABRAXAS1
CC       (phosphorylated form). Component of the BRCA1-RBBP8 complex. Interacts
CC       (via the BRCT domains) with RBBP8 ('Ser-327' phosphorylated form); the
CC       interaction ubiquitinates RBBP8, regulates CHEK1 activation, and
CC       involves RBBP8 in BRCA1-dependent G2/M checkpoint control on DNA
CC       damage. Associates with RNA polymerase II holoenzyme. Interacts with
CC       SMC1A, NELFB, DCLRE1C, CLSPN. CHEK1, CHEK2, BAP1, BRCC3, UBXN1 and
CC       PCLAF. Interacts (via BRCT domains) with BRIP1 (phosphorylated form).
CC       Interacts with FANCD2 (ubiquitinated form). Interacts with H2AX
CC       (phosphorylated on 'Ser-140'). Interacts (via the BRCT domains) with
CC       ACACA (phosphorylated form); the interaction prevents dephosphorylation
CC       of ACACA. Part of a BRCA complex containing BRCA1, BRCA2 and PALB2.
CC       Interacts directly with PALB2; the interaction is essential for its
CC       function in HRR. Interacts directly with BRCA2; the interaction occurs
CC       only in the presence of PALB2 which serves as the bridging protein.
CC       Interacts (via the BRCT domains) with LMO4; the interaction represses
CC       the transcriptional activity of BRCA1. Interacts (via the BRCT domains)
CC       with CCAR2 (via N-terminus); the interaction represses the
CC       transcriptional activator activity of BRCA1 (By similarity). Interacts
CC       with EXD2 (By similarity). Interacts (via C-terminus) with DHX9; this
CC       interaction is direct and links BRCA1 to the RNA polymerase II
CC       holoenzyme (By similarity). Interacts with DNA helicase ZGRF1; the
CC       interaction is increased following DNA damage induction (By
CC       similarity). {ECO:0000250|UniProtKB:P38398}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P38398}.
CC       Chromosome {ECO:0000250|UniProtKB:P48754}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P38398}. Note=Localizes at sites of DNA damage
CC       at double-strand breaks (DSBs); recruitment to DNA damage sites is
CC       mediated by the BRCA1-A complex. Translocated to the cytoplasm during
CC       UV-induced apoptosis. {ECO:0000250|UniProtKB:P38398}.
CC   -!- DOMAIN: The BRCT domains recognize and bind phosphorylated pSXXF motif
CC       on proteins. The interaction with the phosphorylated pSXXF motif of
CC       ABRAXAS1, recruits BRCA1 at DNA damage sites.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- DOMAIN: The RING-type zinc finger domain interacts with BAP1.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Phosphorylated in response to IR, UV, and various stimuli that
CC       cause checkpoint activation, probably by ATM or ATR. Phosphorylation at
CC       Ser-975 by CHEK2 regulates mitotic spindle assembly. Phosphorylation by
CC       AURKA regulates centrosomal microtubule nucleation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination.
CC       'Lys-6'-linked polyubiquitination does not promote degradation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF036760; AAC36493.1; -; mRNA.
DR   EMBL; S82504; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S82502; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U60523; AAB40387.1; -; mRNA.
DR   EMBL; S82500; AAB37501.1; -; Genomic_DNA.
DR   RefSeq; NP_036646.1; NM_012514.1.
DR   PDB; 1L0B; X-ray; 2.30 A; A=1589-1817.
DR   PDBsum; 1L0B; -.
DR   SMR; O54952; -.
DR   STRING; 10116.ENSRNOP00000072366; -.
DR   iPTMnet; O54952; -.
DR   PhosphoSitePlus; O54952; -.
DR   PaxDb; 10116-ENSRNOP00000028109; -.
DR   GeneID; 497672; -.
DR   KEGG; rno:497672; -.
DR   UCSC; RGD:2218; rat.
DR   AGR; RGD:2218; -.
DR   CTD; 672; -.
DR   RGD; 2218; Brca1.
DR   eggNOG; KOG4362; Eukaryota.
DR   InParanoid; O54952; -.
DR   OrthoDB; 5405431at2759; -.
DR   PhylomeDB; O54952; -.
DR   Reactome; R-RNO-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-RNO-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-RNO-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-RNO-5689901; Metalloprotease DUBs.
DR   Reactome; R-RNO-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-RNO-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-RNO-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-RNO-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-RNO-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-RNO-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-RNO-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-RNO-69473; G2/M DNA damage checkpoint.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; O54952; -.
DR   PRO; PR:O54952; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0070531; C:BRCA1-A complex; ISO:RGD.
DR   GO; GO:0070532; C:BRCA1-B complex; ISO:RGD.
DR   GO; GO:0031436; C:BRCA1-BARD1 complex; ISS:UniProtKB.
DR   GO; GO:0070533; C:BRCA1-C complex; ISO:RGD.
DR   GO; GO:0005694; C:chromosome; ISS:UniProtKB.
DR   GO; GO:0000793; C:condensed chromosome; ISO:RGD.
DR   GO; GO:0000794; C:condensed nuclear chromosome; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:1990391; C:DNA repair complex; ISO:RGD.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; ISO:RGD.
DR   GO; GO:0000800; C:lateral element; ISO:RGD.
DR   GO; GO:0001673; C:male germ cell nucleus; ISO:RGD.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:RGD.
DR   GO; GO:0000152; C:nuclear ubiquitin ligase complex; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:1990904; C:ribonucleoprotein complex; ISO:RGD.
DR   GO; GO:0001741; C:XY body; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; IDA:RGD.
DR   GO; GO:0003684; F:damaged DNA binding; ISO:RGD.
DR   GO; GO:0001216; F:DNA-binding transcription activator activity; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0002039; F:p53 binding; ISO:RGD.
DR   GO; GO:0003723; F:RNA binding; ISO:RGD.
DR   GO; GO:0070063; F:RNA polymerase binding; ISS:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; ISO:RGD.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; ISO:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; ISO:RGD.
DR   GO; GO:0007098; P:centrosome cycle; ISO:RGD.
DR   GO; GO:0043009; P:chordate embryonic development; ISO:RGD.
DR   GO; GO:0007059; P:chromosome segregation; ISO:RGD.
DR   GO; GO:0006974; P:DNA damage response; ISO:RGD.
DR   GO; GO:0006302; P:double-strand break repair; ISO:RGD.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; ISO:RGD.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISO:RGD.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint signaling; ISO:RGD.
DR   GO; GO:0044818; P:mitotic G2/M transition checkpoint; ISO:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; ISO:RGD.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0044027; P:negative regulation of gene expression via chromosomal CpG island methylation; ISO:RGD.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; ISO:RGD.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:RGD.
DR   GO; GO:0045739; P:positive regulation of DNA repair; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; ISO:RGD.
DR   GO; GO:0006301; P:postreplication repair; ISO:RGD.
DR   GO; GO:0051865; P:protein autoubiquitination; ISS:UniProtKB.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; ISO:RGD.
DR   GO; GO:0060816; P:random inactivation of X chromosome; ISO:RGD.
DR   GO; GO:0051726; P:regulation of cell cycle; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0033595; P:response to genistein; IEP:RGD.
DR   GO; GO:0010212; P:response to ionizing radiation; ISO:RGD.
DR   GO; GO:0033993; P:response to lipid; IEP:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0007549; P:sex-chromosome dosage compensation; IBA:GO_Central.
DR   CDD; cd17735; BRCT_BRCA1_rpt1; 1.
DR   CDD; cd17721; BRCT_BRCA1_rpt2; 1.
DR   CDD; cd16498; RING-HC_BRCA1; 1.
DR   DisProt; DP03051; -.
DR   Gene3D; 3.40.50.10190; BRCT domain; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   IDEAL; IID50304; -.
DR   InterPro; IPR011364; BRCA1.
DR   InterPro; IPR031099; BRCA1-associated.
DR   InterPro; IPR025994; BRCA1_serine_dom.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR13763:SF0; BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN; 1.
DR   PANTHER; PTHR13763; BREAST CANCER TYPE 1 SUSCEPTIBILITY PROTEIN BRCA1; 1.
DR   Pfam; PF00533; BRCT; 2.
DR   Pfam; PF12820; BRCT_assoc; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   PIRSF; PIRSF001734; BRCA1; 1.
DR   PRINTS; PR00493; BRSTCANCERI.
DR   SMART; SM00292; BRCT; 2.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52113; BRCT domain; 2.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS50172; BRCT; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cell cycle; Chromosome; Cytoplasm;
KW   DNA damage; DNA recombination; DNA repair; DNA-binding;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Isopeptide bond;
KW   Lipid biosynthesis; Lipid metabolism; Metal-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1817
FT                   /note="Breast cancer type 1 susceptibility protein homolog"
FT                   /id="PRO_0000055835"
FT   DOMAIN          1588..1682
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1701..1800
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   ZN_FING         24..65
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          313..347
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          529..560
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          617..768
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          875..907
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          959..982
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1145..1180
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1259..1290
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1354..1381
FT                   /note="Interaction with PALB2"
FT                   /evidence="ECO:0000250"
FT   REGION          1373..1534
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           497..503
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        529..557
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        626..655
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        659..690
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        752..768
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        889..904
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        959..979
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1145..1163
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1259..1280
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1406..1431
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1456..1488
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         686
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         706
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48754"
FT   MOD_RES         717
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48754"
FT   MOD_RES         975
FT                   /note="Phosphoserine; by CHEK2"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1153
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1155
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1181
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1304
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1351
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1482
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        109
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        299
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        337
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        457
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        513
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        578
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        1049
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CONFLICT        38
FT                   /note="Q -> K (in Ref. 2; AAB40387/AAB37501)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        192
FT                   /note="A -> M (in Ref. 2; AAB40387/AAB37501)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1597..1602
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1605..1617
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1632..1635
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1641..1643
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1647..1654
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1658..1661
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1663..1669
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   TURN            1670..1672
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1678..1680
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   TURN            1686..1688
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1690..1692
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1694..1701
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1710..1713
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1718..1720
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1722..1731
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1735..1737
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1739..1741
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1743..1745
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1752..1755
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   STRAND          1777..1779
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1781..1788
FT                   /evidence="ECO:0007829|PDB:1L0B"
FT   HELIX           1795..1798
FT                   /evidence="ECO:0007829|PDB:1L0B"
SQ   SEQUENCE   1817 AA;  199879 MW;  C0B4760F0E349A01 CRC64;
     MDLSAVRIQE VQNVLHAMQK ILECPICLEL IKEPVSTQCD HIFCKFCMLK LLNQKKGPSQ
     CPLCKNEITK RSLQGSARFS QLVEELLKII DAFELDTGMQ CANGFSFSKK KNSSSELLNE
     DASIIQSVGY RNRVKKLQQI ESGSATLKDS LSVQLSNLGI VRSMKKNRQT QPQNKSVYIA
     LESDSSEERV NAPDGCSVRD QELFQIAPGG AGDEGKLNSA KKAACDFSEG IRNIEHHQCS
     DKDLNPTENH ATERHPEKCP RISVANVHVE PCGTDARASS LQRGTRSLLF TEDRLDAEKA
     EFCDRSKQSG AAVSQQSRWA DSKETCNGRP VPRTEGKADP NVDSLCGRKQ WNHPKSLCPE
     NSGATTDVPW ITLNSSIQKV NEWFSRTGEM LTSDNASDRR PASNAEAAVV LEVSNEVDGC
     FSSSKKIDLV APDPDNAVMC TSGRDFSKPV ENIINDKIFG KTYQRKGSRP HLNHVTEIIG
     TFTTEPQIIQ EQPFTNKLKR KRSTCLHPED FIKKADLTVV QRISENLNQG TDQMEPNDQA
     MSITSNGQEN RATGNDLQRG RNAHPIESLR KEPAFTAKAK SISNSISDLE VELNVHSSKA
     PKKNRLRRKS TRCVLPLEPI SRNPSPPTCA ELQIESCGSS EETKKNNSNQ TPAGHIREPQ
     LIEDTEPAAD AKKNEPNEHI RKRSASDAFP EEKLMNKAGL LTSCSSPRKP QGPVNPSPER
     KGIEQLEMCQ MPDNNKELGD LVLGGEPSGK PTEPSEESTS VSLVPDTDYD TQNSVSILEA
     NTVRYARTGS VQCMTQFVAS ENPKELVHGS NNAGSGSECF KHPLRHELNH NQETIEMEDS
     ELDTQYLQNT FQVSKRQSFA LFSKLRSPQK DCTLVGARSV PSREPSPKVT SRGEQKERQG
     QEESEISHVQ AVTVTVGLPV PCQEGKPGAV TMCADVSRLC PSSHYRSCEN GLNTTDKSGI
     SQNSHFRQSV SPLRSSIKTD NRKTLTEGRF EKHTERGMGN ETAVQSTIHT ISLNNRGDAC
     LEASSGSVIE VHSTGENVQG QLDRNRGPKV NTVSLLDSTQ PGVSKQSAPV SDKYLEIKQE
     SKAVSADFSP CLFSDHLEKP MRSDKTFQVC SETPDDLLDD VEIQENASFG EGGITEKSAI
     FNGSVLRRES SRSPSPVTHA SKSRSLHRGS RKLEFSEESD STEDEDLPCF QHLLSRVSST
     PELTRCSSVV TQRVPEKAKG TQAPRKSSIS DCNNEVILGE ASQEYQFSED AKCSGSMFSS
     QHSAALGSPA NALSQDPDFN PPSKQRRHQA ENEEAFLSDK ELISDHEDMA ACLEEASDQE
     EDSIIPDSVA SGYESEANLS EDCSQSDILT TQQRATMKDN LIKLQQEMAQ LEAVLEQHGS
     QPSGHPPCLP ADPCALEDLP DPEQNRSGTA ILTSKNINEN PVSQNPKRAC DDKSQPQPPD
     GLPSGDKESG MRRPSPFKSP LTSSRCSARG HSRSLQNRNS TSQEELLQPA XLEKSCEPHN
     LTGRSCLPRQ DLEGTPYPES GIRLVSSRDP DSESPKVSAL VCTAPASTSA LKISQGQVAG
     SCRSPAAGGA DTAVVEIVSK IKPEVTSPKE RAERDISMVV SGLTPKEVMI VQKFAEKYRL
     ALTDVITEET THVIIKTDAE FVCERTLKYF LGIAGGKWIV SYSWVIKSIQ ERKLLSVHEF
     EVKGDVVTGS NHQGPRRSRE SQEKLFEGLQ IYCCEPFTNM PKDELERMLQ LCGASVVKEL
     PLLTRDTGAH PIVLVQPSAW TEDNDCPDIG QLCKGRLVMW DWVLDSISVY RCRDLDAYLV
     QNITCGRDGS EPQDSND
//
